ResourcePath is a biotechnology and health care startup founded in 2020. The company operates as a CLIA-certified, CAP-accredited laboratory, with a focus on developing and validating diagnostic tests. Led by a team of experienced pathologists, public health professionals, and scientists, ResourcePath specializes in molecular diagnostic technologies such as sequencing, PCR, ddPCR, ELISA, and gene expression analysis. The company's dedication lies in advancing diagnostics and enhancing patient care through innovative and reliable solutions, as well as by forming strategic partnerships within the industry. ResourcePath's expertise spans from pathogen detection to biomarker discovery, aiming to revolutionize the field of diagnostic medicine. As of now, there is no publicly available information regarding ResourcePath's headquarters, last investment, or investors. However, given the industry focus and the growing demand for advanced diagnostic solutions, ResourcePath presents an intriguing investment opportunity for venture capitalists looking to support the future of diagnostic technology.
There is no investment information
No recent news or press coverage available for ResourcePath.
We care about your data, and we'd love to use cookies make your experience better.
